Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?

Shammim Haji, MPharm, Jignesh P Patel, PhD, Vivian Auyeung, PhD, Lara N Roberts, MD, Julia Czuprynska, MBBS, Raj K Patel, MD, Roopen Arya, PhD

Blood (2015) 126 (23): 2335.

https://doi.org/10.1182/blood.V126.23.2335.2335

Published: 2015

Journal Articles

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Khine Z Win, MD, Nathan Wilson, PharmD, David D Stenehjem, PharmD, Natalee Tanner, PharmD, George M. Rodgers, MD PhD, Jeffrey Gilreath, PharmD

Blood (2015) 126 (23): 2319.

https://doi.org/10.1182/blood.V126.23.2319.2319

Published: 2015

Journal Articles

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Christina Köhler, MD, Sebastian Werth, MD, Luise Tittl, Jan Beyer-Westendorf, MD

Blood (2013) 122 (21): 2380.

https://doi.org/10.1182/blood.V122.21.2380.2380

Published: 2013

Journal Articles

Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease

Simon Mantha, MD, MPH, Jack Ansell, MD

Blood (2013) 122 (21): 3640.

https://doi.org/10.1182/blood.V122.21.3640.3640

Published: 2013

Journal Articles

Comparative Efficacy and Safety Of Dabigatran Etexilate and Rivaroxaban For The Treatment Of Deep Vein Thrombosis and Pulmonary Embolism

Andreas Clemens, MD, Shaun Abeysinghe, PhD, Ann-Katrin Gonschior, PhD, Volker Hösel, PhD, Sarah Lock, BSc, Sorrel E Wolowacz, PhD, Mathew Woods, MSc, Evelina Zimovetz, MSc

Blood (2013) 122 (21): 4807.

https://doi.org/10.1182/blood.V122.21.4807.4807

Published: 2013

Journal Articles

Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE

Martin Gebel, PhD, Martin Prins, MD, Anthonie WA Lensing, MD

Blood (2013) 122 (21): 1135.

https://doi.org/10.1182/blood.V122.21.1135.1135

Published: 2013

Journal Articles

Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy

Petra MG Erkens, PhD, Gregory J Fermann, MD, FACEP, Martin H Prins, MD, Philip S Wells, MD, MSc, Akos F Pap, MSc, Anthonie WA Lensing, MD

Blood (2013) 122 (21): 1139.

https://doi.org/10.1182/blood.V122.21.1139.1139

Published: 2013

Journal Articles

Patient-Reported Treatment Satisfaction with Oral Rivaroxaban Versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism

Martin Prins, MD, PhD, Luke Bamber, Stefan Cano, Maria Wang, Anthonie WA Lensing, Rupert Bauersachs

Blood (2012) 120 (21): 1163.

https://doi.org/10.1182/blood.V120.21.1163.1163

Published: 2012

Journal Articles

Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Craig D. Seaman, MD, Margaret V. Ragni, MD, MPH, Kenneth J. Smith, MD, MS

Blood (2012) 120 (21): 3177.

https://doi.org/10.1182/blood.V120.21.3177.3177

Published: 2012

Journal Articles

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Bonno van Bellen, MD, Martin Prins, MD, PhD, Luke Bamber, Maria Wang, Anthonie WA Lensing

Blood (2012) 120 (21): 3419.

https://doi.org/10.1182/blood.V120.21.3419.3419

Published: 2012

Journal Articles

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Harry Roger Buller, MD, PhD

Blood (2012) 120 (21): 20.

https://doi.org/10.1182/blood.V120.21.20.20

Published: 2012

NARROW

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119)

Indirect Comparison Of Dabigatran, Rivaroxaban and Apixaban For Venous Thromboembolic Disease

Comparative Efficacy and Safety Of Dabigatran Etexilate and Rivaroxaban For The Treatment Of Deep Vein Thrombosis and Pulmonary Embolism

Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE

Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy

Patient-Reported Treatment Satisfaction with Oral Rivaroxaban Versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism

Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only